UCB SA (UCB)
UCB SA engages in the research, development, and commercialization of pharmaceutical and biotechnology products. It offers medicinal products such as briviact, keppra, vimpat, neupro, cimzia, nootropil, xyrem, xyzal, and zyrtec. The company was founded by Emmanuel Janssen on January 18, 1928 and is headquartered in Brussels, Belgium.
|Market Price at 17-11-2017||61,41 €|
|Price to Earnings Ratio||19,09|
|Market Capitalisation||11.550,61 € (million)|
|Return on Equity (ROE)||10,76%|